UDCA Dosage and Duration: How Long to See Results for Gallstones

Standard UDCA dosage for gallstones

If your doctor has prescribed UDCA (ursodeoxycholic acid) for gallstones, one of the first questions you'll have is: how much should I take, and how long before I see results? These are genuinely important questions, because UDCA works slowly — we're talking months, not days — and getting the dose right from the start makes a real difference to how well it works.

UDCA is a bile acid that occurs naturally in small amounts in human bile. At therapeutic doses, it works by changing the composition of bile, making it less saturated with cholesterol so that existing cholesterol gallstones gradually dissolve. It doesn't work on all gallstones — only cholesterol stones that are small, non-calcified, and in a functioning gallbladder — but for the right patient, it can genuinely dissolve stones and avoid surgery. Here's everything you need to know about dosing and what to expect.

Standard UDCA dosage for gallstones

The dose of UDCA is calculated by body weight. The standard therapeutic range is 10–15 mg per kilogram of body weight per day. Most studies have used 500–600 mg/day as the effective dose for patients weighing 50–70 kg, and higher doses in this range don't appear to improve results meaningfully.

• 50 kg patient: 500–750 mg/day
• 60 kg patient: 600–900 mg/day
• 70 kg patient: 700–1050 mg/day (most doctors use 750 mg in practice)
• 80 kg patient: 800–1200 mg/day

The daily dose is divided — usually into two doses taken with the morning and evening meals, or three doses with each main meal. Taking UDCA with food is important: it significantly improves absorption and reduces the chance of loose stools, which is the most common side effect at higher doses.

UDCA is available in 150 mg, 250 mg, and 300 mg capsules or tablets in India, under brand names including Urdoxa, Udiliv, and Ursocol. Your gastroenterologist will choose the formulation that allows the closest approximation to your weight-based dose.

Timeline: how long until you see results?

This is where patients often feel frustrated, because UDCA works on a timescale that's very different from most medications. You're not suppressing symptoms — you're dissolving solid stones through a slow chemical process. The timeline depends almost entirely on stone size:

One thing to be clear about: you will not feel your stones dissolving. UDCA does not relieve biliary colic (the sharp upper-right pain from stones moving). If you have pain during treatment, it's from stone movement, not the medication. Some patients become pain-free earlier because smaller fragments move more easily, but this varies.

Monitoring during treatment — ultrasound schedule

You can't see or feel whether UDCA is working — you need ultrasound. A structured monitoring plan is essential to confirm progress and identify non-responders before they waste a further year on ineffective treatment.

• Baseline ultrasound: Before starting, to document stone size, number, and gallbladder wall thickness (a thickened wall may indicate chronic cholecystitis, which reduces UDCA efficacy).
• 6-month ultrasound: First follow-up. If stones have reduced in size or number, this is a good sign — continue treatment. If there's no change at all, discuss with your gastroenterologist whether to continue.
• 12-month ultrasound: If no reduction has occurred by 12 months, UDCA is very unlikely to succeed. This is the standard stopping rule in clinical guidelines.
• After complete dissolution: Repeat ultrasound at 6 months and 12 months post-dissolution to check for recurrence, which occurs in 30–50% of patients within 5 years.

When to stop UDCA (non-responders)

Not everyone responds to UDCA, and it's important to know when to stop rather than continuing indefinitely with no benefit. Stop UDCA if:

• No reduction in stone size or number after 12 months of therapy
• Stones become more calcified (visible on plain X-ray) — calcification blocks UDCA from working
• You develop acute cholecystitis, pancreatitis, or cholangitis — these require surgery, not continued UDCA
• Intolerable side effects (persistent diarrhoea, nausea, or abdominal discomfort that doesn't settle)

Stopping UDCA and proceeding to cholecystectomy is not a failure. A trial of UDCA does not make surgery more difficult. Many patients choose this path after a partial response or as their preferences change.

Factors that influence how fast UDCA works

Why does UDCA work quickly for some patients and slowly (or not at all) for others? Several factors determine how well it works:

• Stone size: The single biggest predictor. Stones under 5 mm dissolve far more reliably and quickly than larger stones.
• Stone number: Solitary stones respond better than multiple stones. With multiple stones, the total cholesterol load is higher.
• Stone composition: UDCA only dissolves cholesterol stones. Pure pigment stones (common in people with sickle cell disease, cirrhosis, or haemolytic anaemia) do not respond at all. Radiolucent stones on plain X-ray are more likely to be cholesterol-based.
• Gallbladder function: A functioning gallbladder that contracts normally after meals is needed. UDCA changes bile composition in the gallbladder — if the gallbladder doesn't empty properly (biliary dyskinesia), the modified bile can't reach the stones effectively.
• Body weight: Obesity slows response. Adipose tissue produces cholesterol, which partially counteracts UDCA's bile-thinning effect. Concurrent lifestyle changes help.
• Adherence: Missing doses — even occasionally — reduces the sustained bile composition change that drives dissolution. Twice-daily dosing with meals is important to maintain.

Maintenance therapy after dissolution

The unfortunate reality is that gallstones come back. Even after complete dissolution, the conditions that caused the stones — bile supersaturated with cholesterol — often persist. Recurrence rates are substantial:

• Year 1: 10–15% recurrence
• Year 3: 25–35% recurrence
• Year 5: 30–50% recurrence

To reduce recurrence, some gastroenterologists recommend continuing UDCA at a lower maintenance dose (typically 300 mg/day or 5 mg/kg/day) for 6–12 months after dissolution. Evidence supports roughly a 50% reduction in recurrence with maintenance therapy, though it is not universally prescribed and may not be covered by insurance as this is an off-label indication in India.

Alongside any medication, lifestyle changes significantly reduce recurrence risk: maintaining a healthy weight (avoiding rapid weight loss, which dramatically increases stone risk), eating regular meals (skipping meals allows bile to stagnate and concentrate), reducing saturated fat, and increasing dietary fibre all help keep bile composition in a less stone-forming range.